Started a cautiously optimistic position today despite following MACK since FierceBio featured them in 2011. I see the value in MM-121 as I feel it validates the "Network Bio" platform but worried that any sub par 3MM-98 results will drag the stock down as it is the lead candidate for the company. As these are not expected until 2014, I'm long in anticipation of positive MM-121 in 2013.
Time will tell, I imagine I am looking forward to the same catalyst that everyone else is.
I would tend to agree, but it's important to realize this company has five cancer drugs in clinical trials---three of which are proprietary and two of which are liposomal repackaging of traditional agents. So any positive results from the three 'in house' compounds: MM121, MM111, or MM151, would confirm their platform and revalue the company.
The two that were liposomal repackaging of traditional agents, do you know if they were organically developed? I feel like I read somewhere they were obtained during an acquistion but I could be wrong.